Both inhibitors are predicted or validated targets of T2D-enriched miRNAs (TIMP2 by miR-93-5p; LACTB by miR-374a), suggesting that luminal-like tumor cells may be key sites of miRNA-driven repression that contributes to broader MMP activation. Here, LACTB is linked to type 2 diabetes mellitus.